Sensei Biotherapeutics Inc
SNSE
Company Profile
Business description
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
Contact
1405 Research Boulevard
Suite 125
RockvilleMD20850
USAT: +1 240 243-8000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,797.20 | 31.50 | -0.36% |
| CAC 40 | 7,766.71 | 43.24 | 0.56% |
| DAX 40 | 24,206.91 | 133.24 | 0.55% |
| Dow JONES (US) | 44,240.76 | 165.60 | -0.37% |
| FTSE 100 | 8,854.18 | 47.65 | 0.54% |
| HKSE | 24,148.07 | 260.24 | 1.09% |
| NASDAQ | 20,418.46 | 5.95 | 0.03% |
| Nikkei 225 | 39,769.48 | 80.67 | 0.20% |
| NZX 50 Index | 12,752.95 | 106.07 | -0.82% |
| S&P 500 | 6,225.52 | 4.46 | -0.07% |
| S&P/ASX 200 | 8,559.00 | 31.70 | -0.37% |
| SSE Composite Index | 3,497.48 | 24.35 | 0.70% |